bioRxivImmunology
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
C. K. Wibmer, F. Ayres, T. Hermanus, M. Madzivhandila, P. Kgagudi, B. Oosthuysen, B. E. Lambson, T. de Oliveira, M. Vermeulen, K. van den Berg, T. Rossouw, M. Boswell, V. Ueckermann, S. Meiring, A. von Gottberg, C. Cohen, L. Morris, J. N. Bhiman, P. L. Moore
Abstract
SARS-CoV-2 501Y.V2 (B.1.351), a novel lineage of coronavirus causing COVID-19, contains substitutions in two immunodominant domains of the spike protein. Here, we show that pseudovirus expressing 501Y.V2 spike protein completely escapes three classes of therapeutically relevant antibodies. This pseudovirus also exhibits substantial to complete escape from neutralization, but not binding, by convalescent plasma. These data highlight the prospect of reinfection with antigenically distinct variants and foreshadows reduced efficacy of spike-based vaccines.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies
T. Moyo-Gwete, M. Madzivhandila, … P. Moore·bioRxiv·Mar 6, 2021
- SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines
X. Shen, H. Tang, … D. Montefiori·bioRxiv·Jan 27, 2021
- SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma
E. Andreano, G. Piccini, … R. Rappuoli·bioRxiv·Dec 28, 2020
- Neutralization of SARS-CoV-2 VOC 501Y.V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines
- Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies
- SARS-CoV-2 variants resist antibody neutralization and broaden host ACE2 usage